<?xml version="1.0" encoding="UTF-8"?><Articles><Article><id>118</id><JournalTitle>FORMULATION AND EVALUATION OF LORNOXICAM EXTENDED RELEASE TABLETS</JournalTitle><Abstract>Most conventional oral drug products, such as tablets and capsules, are formulated to release the active drug
immediately after oral administration, to obtain rapid and complete systemic drug absorption. Such immediate-release products
result in relatively rapid drug absorption and onset of accompanying pharmacodynamic effects. However, after absorption of
the drug from the dosage form is complete, plasma drug concentrations decline according to the drug's pharmacokinetic profile.
Eventually, plasma drug concentrations fall below the minimum effective plasma concentration (MEC), resulting in loss of
therapeutic activity. Before this point is reached, another dose is usually given if a Extended therapeutic effect is desired. An
alternative to administering another dose is to use a dosage form that will provide extended drug release, and therefore maintain
plasma drug concentrations, beyond what is typically seen using immediate-release dosage forms. In recent years, various
modified-release drug products have been developed to control the release rate of the drug and/or the time for drug release.
</Abstract><Email>thejasaipharma@gmail.com</Email><articletype>Research</articletype><volume>8</volume><issue>2</issue><year>2018</year><keyword>Lornoxicam, Extended release, Modern drug delivery, Matrix Tablets.</keyword><AUTHORS>Muni Theja K,Jayachandra Reddy P,Umasankar K</AUTHORS><afflication>Muni Theja K,Jayachandra Reddy P,Umasankar K</afflication></Article></Articles>